Sixty-two represents the highest number of tumor neoantigens targeted by a personalized cancer vaccine, and the vaccination induced in mice a potent T cell response in mice against a number of encoded neoantigens comprising antigen-specific IFN-γ secreting CD8+ and CD4+ T cells. The gene discussed is CD8A; the disease is cancer.